Literature DB >> 17412560

Converting antigen-specific diabetogenic CD4 and CD8 T cells to TGF-beta producing non-pathogenic regulatory cells following FoxP3 transduction.

Jian Peng1, Bridget Dicker, Wei Du, Fengjuan Tang, Phuong Nguyen, Terrence Geiger, F Susan Wong, Li Wen.   

Abstract

Immuno-regulatory defects, including a reduction in the number and function of regulatory T cells, play an important role in the development of autoimmune diabetes in both humans and non-obese diabetic (NOD) mice. In this study we tested the effect of introduction of FoxP3 into antigen non-specific polyclonal and antigen-specific monoclonal T cells on diabetes development in NOD mice. Transduction of FoxP3 into antigen-specific monoclonal (insulin or BDC2.5 mimotope specific) or antigen non-specific polyclonal T cells using retroviral transduction delayed or prevented diabetes development. However, transduced antigen-specific monoclonal T cells were considerably more effective than polyclonal T cells. Regulatory activity was not limited to CD4 T cells as potent diabetogenic CD8 T cells specific for insulin, were also reduced in pathogenicity by FoxP3 induction. The disease suppressive effect, in both CD4 and CD8 cells, was more evident in spontaneously diabetes-prone NOD hosts (non-lymphopenic) than in lymphopenic NOD.scid hosts. We suggest that this strategy of transducing antigen-specific CD4 or CD8 T cells may be a useful therapeutic approach in the prevention of autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412560     DOI: 10.1016/j.jaut.2007.02.015

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  10 in total

1.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  CD8+ regulatory T cells are responsible for GAD-IgG gene-transferred tolerance induction in NOD mice.

Authors:  Renxi Wang; Gencheng Han; Lun Song; Jianan Wang; Guojiang Chen; Ruonan Xu; Ming Yu; Jiahua Qian; Beifen Shen; Yan Li
Journal:  Immunology       Date:  2008-06-20       Impact factor: 7.397

3.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

Authors:  Sander van der Marel; Anna Majowicz; Sander van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

5.  Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells.

Authors:  Hozefa S Bandukwala; Yongqing Wu; Markus Feuerer; Yongheng Chen; Bianca Barboza; Srimoyee Ghosh; James C Stroud; Christophe Benoist; Diane Mathis; Anjana Rao; Lin Chen
Journal:  Immunity       Date:  2011-03-31       Impact factor: 31.745

Review 6.  Animal models of primary biliary cirrhosis.

Authors:  Ya-Hui Chuang; William M Ridgway; Yoshiyuki Ueno; M Eric Gershwin
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

7.  Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.

Authors:  Chang-yun Hu; Daniel Rodriguez-Pinto; Wei Du; Anupama Ahuja; Octavian Henegariu; F Susan Wong; Mark J Shlomchik; Li Wen
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 8.  Regulatory T cells in the prevention of mucosal inflammatory diseases: patrolling the border.

Authors:  Ruth Y Lan; Ian R Mackay; M Eric Gershwin
Journal:  J Autoimmun       Date:  2007-09-21       Impact factor: 7.094

9.  Development of Gene Transfer for Induction of Antigen-specific Tolerance.

Authors:  Brandon K Sack; Roland W Herzog; Cox Terhorst; David M Markusic
Journal:  Mol Ther Methods Clin Dev       Date:  2014-04-30       Impact factor: 6.698

Review 10.  Early Growth Response Gene 2-Expressing CD4+LAG3+ Regulatory T Cells: The Therapeutic Potential for Treating Autoimmune Diseases.

Authors:  Tomohisa Okamura; Kazuhiko Yamamoto; Keishi Fujio
Journal:  Front Immunol       Date:  2018-02-26       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.